Stifel Nicolaus Has Lowered Expectations for DarioHealth (NASDAQ:DRIO) Stock Price

DarioHealth (NASDAQ:DRIO – Get Free Report) had its price objective reduced by equities research analysts at Stifel Nicolaus to $5.00 in a research report issued to clients and investors on Friday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. Stifel Nicolaus‘s price objective suggests a potential upside of 296.83% from the company’s previous close.

Several other research analysts also recently issued reports on DRIO. Alliance Global Partners began coverage on DarioHealth in a research note on Wednesday, August 19th. They set a “buy” rating and a $12.00 price target for the company. TD Cowen cut their target price on shares of DarioHealth from $11.00 to $8.00 and set a “hold” rating for the company in a research report on Wednesday, August 12th. BTIG Research started coverage on shares of DarioHealth in a report on Tuesday, October 27th. They issued a “buy” rating and a $6.00 price target on the stock. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of DarioHealth in a report on Tuesday, October 6th. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $7.75.

Check Out Our Latest Stock Analysis on DarioHealth

DarioHealth Price Performance

NASDAQ DRIO traded down $0.39 during mid-day trading on Friday, hitting $1.26. The stock had a trading volume of 74,793 shares, compared to its average volume of 86,340. DarioHealth has a 52-week low of $1.26 and a 52-week high of $14.77. The company has a market cap of $12.35 million, a price-to-earnings ratio of -0.32 and a beta of 1.18. The company has a 50 day simple moving average of $5.03 and a 200 day simple moving average of $7.32. The company has a quick ratio of 1.92, a current ratio of 2.31 and a debt-to-equity ratio of 0.56.

DarioHealth (NASDAQ:DRIO – Get Free Report) last issued its quarterly earnings data on Thursday, November 12th. The company reported ($0.73) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.95) by $0.22. The firm had revenue of $5.31 million during the quarter, compared to analysts’ expectations of $5.21 million. DarioHealth had a negative return on equity of 55.10% and a negative net margin of 159.85%. Equities analysts forecast that DarioHealth will post -2.94 EPS for the current fiscal year.

Institutional Trading of DarioHealth

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Nantahala Capital Management LLC acquired a new position in DarioHealth in the 2nd quarter valued at about $4,030,561. Commonwealth Equity Services LLC purchased a new position in DarioHealth in the 3rd quarter valued at about $159,000. Finally, BlackRock Inc. purchased a new position in DarioHealth in the 2nd quarter valued at about $249,000. Hedge funds and other institutional investors own 33.39% of the company’s stock.

Trending Headlines about DarioHealth

These are some of the DRIO headlines that stood out recently:

  • Positive Sentiment: Management said contracted and late-stage annual recurring revenue totaled $13.1 million across more than 180 accounts, with over 80% tied to multi-condition opportunities. It expects revenue growth to accelerate late in 2026 and into 2027 as committed ARR converts, and cited a new New Jersey health-plan customer covering 1.5 million people. DarioHealth Q3 results
  • Positive Sentiment: Stifel Nicolaus lowered its price target to $5 but maintained a Buy rating, indicating that the analyst still sees substantial potential upside from the referenced share price. Stifel Nicolaus ratings
  • Neutral Sentiment: Despite the improving operating trends, DarioHealth remains loss-making, and GAAP gross margin edged down to 59% from 60% a year earlier. The forecasted growth depends on converting contracted and late-stage opportunities, so execution and the timing of revenue remain key risks. DarioHealth Q3 results

About DarioHealth

(Get Free Report)

DarioHealth Corp. is a digital health company that develops technology-enabled programs to help people manage chronic and behavioral health conditions. Its offerings combine mobile applications, connected devices, coaching and personalized guidance. The company’s services address conditions including diabetes, hypertension, weight management, musculoskeletal health and behavioral health. Its platform is designed to support individuals as well as employers and health plans seeking to provide digital health programs to their members.

Further Reading

Analyst Recommendations for DarioHealth (NASDAQ:DRIO)

Receive News & Ratings for DarioHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DarioHealth and related companies with MarketBeat.com's FREE daily email newsletter.